ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer

Toxicities Associated With Rucaparib for the Treatment of Ovarian Cancer

Jonathan Ledermann, MD
Published Online: 12:23 PM, Fri September 8, 2017

Jonathan Ledermann, MD, professor of medical oncology in the University College London Cancer Institute and director of Cancer Research UK and UCL Cancer Trials Centre, discusses the toxicities associated with rucaparib (Rubraca) for the treatment of ovarian cancer.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.